Last reviewed · How we verify
NCT05109884
Comparison of PET Imaging Patterns With PSMA and AR Expression in Prostate Cancer and Bladder Cancer
NA trial testing PSMA PET Scan in Prostate Cancer in 10 participants. Completed in 19 April 2021.
19 April 2021
Quick facts
| Lead sponsor | Medical University of Vienna |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 10 |
| Start date | 1 February 2020 |
| Primary completion | 19 April 2021 |
| Estimated completion | 19 April 2021 |
| Sites | 1 location across Austria |
Drugs / interventions tested
- PSMA PET Scan
- FDHT PET Scan
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
Sponsor
Medical University of Vienna
Who can join
Adults 18 to 75, any sex, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients suffering either from newly diagnosed very high risk locally advanced and/or oligometastatic prostate cancer (cohort A), metastatic castration-resistant prostate cancer (mCRPC, cohort B), newly diagnosed postate cancer with planned radical prostatectomy (cohort C) or primary bladder cancer with planned radical cystectomy (cohort D) as identified by a multidisciplinary team of specialists, will be included. PET imaging patterns using PSMA- and FDHT PET scans will be correlated with prostate-specific membrane antigen and androgen specific receptor expression patterns in prostate cancer and bladder cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05109884
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PSMA PET Scan
Trials testing the same drug.
- NCT06982222 — Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones · Phase 1 · not yet recruiting
- NCT07468903 — Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer · NA · not yet recruiting
- NCT07219147 — 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer · Phase 1 · recruiting
- NCT06931340 — Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastati · Phase 3 · recruiting
- NCT07200830 — Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Adva · Phase 3 · not yet recruiting
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other Medical University of Vienna trials
Trials by the same sponsor.
- NCT07473401 — Retinal Oxygen Metabolism in Children With Myopia · not yet recruiting
- NCT07511400 — The Role of NaV1.8 in Human Pain Models · EARLY_PHASE1 · not yet recruiting
- NCT07516990 — Intramuscular Injection of Mashed Parathyroid Tissue Into a Forearm During Thyroid Surgery to Prevent Permanent Postoper · NA · recruiting
- NCT07496437 — Is Cross-linked Hyaluronic Acid a Biologic Alternative for Alveolar Ridge Preservation? · NA · not yet recruiting
- NCT07290712 — Post-Intensive Care Syndrome - Multicentre Prospective Registry Database of the DACH Region · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05109884 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medical University of Vienna
- Last refreshed: 17 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05109884.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing